Humana (NYSE:HUM) had its target price raised by stock analysts at Morgan Stanley from $400.00 to $418.00 in a note issued to investors on Thursday. The firm currently has a “buy” rating on the insurance provider’s stock. Morgan Stanley’s price target would indicate a potential upside of 23.32% from the stock’s previous close.
HUM has been the topic of several other reports. MED lifted their price target on Humana from $350.00 to $373.00 and gave the stock an “outperform” rating in a research report on Thursday. Piper Jaffray Companies lifted their price objective on Humana from $355.00 to $380.00 and gave the stock an “overweight” rating in a report on Friday, August 24th. Bank of America lifted their price objective on Humana from $338.00 to $375.00 and gave the stock a “buy” rating in a report on Thursday, August 2nd. Royal Bank of Canada reissued a “hold” rating and set a $318.00 price objective on shares of Humana in a report on Thursday, August 2nd. Finally, SunTrust Banks lifted their price objective on Humana to $380.00 and gave the stock a “hold” rating in a report on Wednesday, September 19th. Seven equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $352.30.
Shares of NYSE HUM opened at $338.95 on Thursday. The company has a current ratio of 1.43, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $48.77 billion, a price-to-earnings ratio of 25.36, a price-to-earnings-growth ratio of 1.73 and a beta of 1.03. Humana has a 12 month low of $231.90 and a 12 month high of $355.88.
In related news, CEO Bruce D. Broussard sold 18,000 shares of the business’s stock in a transaction on Monday, September 10th. The stock was sold at an average price of $328.66, for a total value of $5,915,880.00. Following the sale, the chief executive officer now owns 71,085 shares of the company’s stock, valued at approximately $23,362,796.10. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Elizabeth D. Bierbower sold 3,092 shares of the business’s stock in a transaction on Thursday, August 16th. The shares were sold at an average price of $330.00, for a total value of $1,020,360.00. Following the completion of the sale, the insider now directly owns 14,289 shares in the company, valued at approximately $4,715,370. The disclosure for this sale can be found here. 0.60% of the stock is currently owned by company insiders.
A number of hedge funds have recently made changes to their positions in the stock. FMR LLC boosted its stake in Humana by 1.4% in the 3rd quarter. FMR LLC now owns 12,379,797 shares of the insurance provider’s stock valued at $4,190,809,000 after buying an additional 167,283 shares in the last quarter. BlackRock Inc. boosted its stake in Humana by 1.2% in the 3rd quarter. BlackRock Inc. now owns 12,311,736 shares of the insurance provider’s stock valued at $4,167,767,000 after buying an additional 140,731 shares in the last quarter. Northern Trust Corp boosted its stake in Humana by 1.2% in the 2nd quarter. Northern Trust Corp now owns 1,687,211 shares of the insurance provider’s stock valued at $502,164,000 after buying an additional 20,480 shares in the last quarter. Acadian Asset Management LLC raised its position in Humana by 7.6% in the 2nd quarter. Acadian Asset Management LLC now owns 1,324,681 shares of the insurance provider’s stock valued at $394,262,000 after purchasing an additional 93,021 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in Humana by 4.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 804,090 shares of the insurance provider’s stock valued at $272,199,000 after purchasing an additional 35,845 shares during the last quarter. 92.62% of the stock is currently owned by institutional investors and hedge funds.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Read More: Dividend Aristocrat Index
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.